– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
Eisai and Biogen’s Supplemental Biologics License Application (sBLA) for Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) has been accepted by the US FDA under Priority Review to treat early ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous (SC) injection to patients with ...
Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...
Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial ...
While administering monoclonal antibodies via intravenous infusion is standard practice to prevent severe hospitalization and death in outpatients with COVID-19, new research from UPMC shows giving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results